Qing-Fen Zhou, Qiu-Ya Lu, Yang Dai, Qiu-Jing Chen, Xiao-Shuang He, Shuai Chen, Jun-Tao Zhao, Feng-Ru Zhang, Lin Lu, Fan Yang
{"title":"苯丙氨酸在预测慢性心力衰竭患者心房颤动风险中的价值。","authors":"Qing-Fen Zhou, Qiu-Ya Lu, Yang Dai, Qiu-Jing Chen, Xiao-Shuang He, Shuai Chen, Jun-Tao Zhao, Feng-Ru Zhang, Lin Lu, Fan Yang","doi":"10.3389/fcvm.2024.1392548","DOIUrl":null,"url":null,"abstract":"<p><strong>Backgrounds: </strong>Atrial fibrillation (AF) is a common complication of chronic heart failure (HF). Serum phenylalanine (Phe) levels are related to inflammation disorder. It is meaningful to study the circulating Phe with AF occurrence in HF.</p><p><strong>Methods: </strong>The cross-sectional study recruited 300 patients (78.0% male; mean age, 65 ± 13 years) with HF (left ventricular ejection fraction of ≤50%, containing 70 AF patients) and 100 normal controls. Serum Phe value was measured by liquid chromatography-tandem mass spectrometry. Logistic regression analysis was conducted to measure the association between Phe and AF risk in HF. The association between Phe and high-sensitivity C-reactive protein (hsCRP) was assessed by simple correlation analysis. In the prospective study, the 274 HF subjects (76.6% male; mean age, 65 ± 13 years) were followed up for a mean year (10.99 ± 3.00 months).</p><p><strong>Results: </strong>Serum Phe levels increased across the control, the HF without AF, and the HF with AF groups (77.60 ± 8.67 umol/L vs. 95.24 ± 28.58 umol/L vs. 102.90 ± 30.43 umol/L, ANOVA <i>P</i> < 0.001). Serum Phe value was the independent risk factor for predicting AF in HF [odds ratio (OR), 1.640; 95% CI: 1.150-2.339; <i>P</i> = 0.006]. Phe levels were correlated positively with hsCRP value in HF patients with AF (<i>r</i> = 0.577, <i>P</i> < 0.001). The elevated Phe levels were associated with a higher risk of HF endpoint events in HF patients with AF (log-rank <i>P</i> = 0.005).</p><p><strong>Conclusions: </strong>In HF with AF subjects, elevated Phe value confers an increased risk for prediction AF and was more related to poor HF endpoint events. Phe can be a valuable index of AF in HF.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368762/pdf/","citationCount":"0","resultStr":"{\"title\":\"The value of phenylalanine in predicting atrial fibrillation risk in chronic heart failure.\",\"authors\":\"Qing-Fen Zhou, Qiu-Ya Lu, Yang Dai, Qiu-Jing Chen, Xiao-Shuang He, Shuai Chen, Jun-Tao Zhao, Feng-Ru Zhang, Lin Lu, Fan Yang\",\"doi\":\"10.3389/fcvm.2024.1392548\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Backgrounds: </strong>Atrial fibrillation (AF) is a common complication of chronic heart failure (HF). Serum phenylalanine (Phe) levels are related to inflammation disorder. It is meaningful to study the circulating Phe with AF occurrence in HF.</p><p><strong>Methods: </strong>The cross-sectional study recruited 300 patients (78.0% male; mean age, 65 ± 13 years) with HF (left ventricular ejection fraction of ≤50%, containing 70 AF patients) and 100 normal controls. Serum Phe value was measured by liquid chromatography-tandem mass spectrometry. Logistic regression analysis was conducted to measure the association between Phe and AF risk in HF. The association between Phe and high-sensitivity C-reactive protein (hsCRP) was assessed by simple correlation analysis. In the prospective study, the 274 HF subjects (76.6% male; mean age, 65 ± 13 years) were followed up for a mean year (10.99 ± 3.00 months).</p><p><strong>Results: </strong>Serum Phe levels increased across the control, the HF without AF, and the HF with AF groups (77.60 ± 8.67 umol/L vs. 95.24 ± 28.58 umol/L vs. 102.90 ± 30.43 umol/L, ANOVA <i>P</i> < 0.001). Serum Phe value was the independent risk factor for predicting AF in HF [odds ratio (OR), 1.640; 95% CI: 1.150-2.339; <i>P</i> = 0.006]. Phe levels were correlated positively with hsCRP value in HF patients with AF (<i>r</i> = 0.577, <i>P</i> < 0.001). The elevated Phe levels were associated with a higher risk of HF endpoint events in HF patients with AF (log-rank <i>P</i> = 0.005).</p><p><strong>Conclusions: </strong>In HF with AF subjects, elevated Phe value confers an increased risk for prediction AF and was more related to poor HF endpoint events. Phe can be a valuable index of AF in HF.</p>\",\"PeriodicalId\":12414,\"journal\":{\"name\":\"Frontiers in Cardiovascular Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368762/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cardiovascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fcvm.2024.1392548\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2024.1392548","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:心房颤动(AF)是慢性心力衰竭(HF)的常见并发症。血清苯丙氨酸(Phe)水平与炎症紊乱有关。研究循环苯丙氨酸与心房颤动发生的关系很有意义:横断面研究招募了 300 名高血压患者(78.0% 为男性;平均年龄为 65 ± 13 岁)(左心室射血分数≤50%,其中包括 70 名房颤患者)和 100 名正常对照组。血清 Phe 值通过液相色谱-串联质谱法测定。对Phe与高频房颤风险之间的关系进行了逻辑回归分析。通过简单相关分析评估了 Phe 与高敏 C 反应蛋白(hsCRP)之间的关系。在这项前瞻性研究中,对 274 名高频受试者(76.6% 为男性;平均年龄为 65 ± 13 岁)进行了平均一年(10.99 ± 3.00 个月)的随访:血清 Phe 水平在对照组、无房颤的高房颤组和有房颤的高房颤组中均有所增加(77.60 ± 8.67 umol/L vs. 95.24 ± 28.58 umol/L vs. 102.90 ± 30.43 umol/L,方差分析 P P = 0.006]。在房颤的高频患者中,Phe水平与hsCRP值呈正相关(r = 0.577,P P = 0.005):结论:在心房颤动的高频患者中,Phe值升高会增加预测心房颤动的风险,并且与心房颤动终点不良事件的关系更为密切。Phe可作为房颤的重要指标。
The value of phenylalanine in predicting atrial fibrillation risk in chronic heart failure.
Backgrounds: Atrial fibrillation (AF) is a common complication of chronic heart failure (HF). Serum phenylalanine (Phe) levels are related to inflammation disorder. It is meaningful to study the circulating Phe with AF occurrence in HF.
Methods: The cross-sectional study recruited 300 patients (78.0% male; mean age, 65 ± 13 years) with HF (left ventricular ejection fraction of ≤50%, containing 70 AF patients) and 100 normal controls. Serum Phe value was measured by liquid chromatography-tandem mass spectrometry. Logistic regression analysis was conducted to measure the association between Phe and AF risk in HF. The association between Phe and high-sensitivity C-reactive protein (hsCRP) was assessed by simple correlation analysis. In the prospective study, the 274 HF subjects (76.6% male; mean age, 65 ± 13 years) were followed up for a mean year (10.99 ± 3.00 months).
Results: Serum Phe levels increased across the control, the HF without AF, and the HF with AF groups (77.60 ± 8.67 umol/L vs. 95.24 ± 28.58 umol/L vs. 102.90 ± 30.43 umol/L, ANOVA P < 0.001). Serum Phe value was the independent risk factor for predicting AF in HF [odds ratio (OR), 1.640; 95% CI: 1.150-2.339; P = 0.006]. Phe levels were correlated positively with hsCRP value in HF patients with AF (r = 0.577, P < 0.001). The elevated Phe levels were associated with a higher risk of HF endpoint events in HF patients with AF (log-rank P = 0.005).
Conclusions: In HF with AF subjects, elevated Phe value confers an increased risk for prediction AF and was more related to poor HF endpoint events. Phe can be a valuable index of AF in HF.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.